Clinical practice guideline on asthma (part II);Guía de práctica clínica sobre asma (2.a parte)

Anales de Pediatria

Volumn 65, Issue 1, 2006, Pages 51-66

  Merino Hernandez M ^a,a   Aranguren Castro, J ^b   Callen Blecua M ^c,l   Elorz Lambarri, J ^d   Etxeberria Agirre, A ^e   Galdiz Iturri, J B ^d   Irizar Aranburu I ^f   Lekue Alkorta, I ^e   Lizarraga Azparren, M A ^g   Maeztu Lopez De Alda M ^b   Marques Gonzalez Ma L ^h   Martinez Gonzalez A ⁱ   Merino Nazabal J M ^a   Rotaeche Del Campo, R ^j   Villar Alvarez M ^k  

^a HOSPITAL DONOSTIA   (Spain)

^b Centro de Salud Lutxana   (Spain)

^c Centro de Salud Bidebieta   (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e Farmacéutica de Atención Primaria   (Spain)

^f Centro de Salud Idiazabal   (Spain)

^g Centro de Salud Erandio   (Spain)

^h Centro de Salud de Leioa   (Spain)

ⁱ Centro de Salud La Paz   (Spain)

^j Centro de Salud Alza   (Spain)

^k HOSPITAL DE BASURTO   (Spain)

^l Hospital de Basurto ^*  (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUTICASONE; IMMUNOMODULATING AGENT; MONTELUKAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; ZAFIRLUKAST;

ASTHMA; BRONCHUS HYPERREACTIVITY; DRUG DOSE REGIMEN; HUMAN; PRACTICE GUIDELINE; REVIEW; SYMPTOMATOLOGY;

EID: 33748430845     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090898     Document Type: Article

References (83)

1. British guideline on the management of asthma. A national clinical guideline. Revisted edition April 2004. Edinburgh; 2004.
2. New Zealand Guidelines Group. The diagnosis and treatment of adult asthma. Disponible en: http://www.nzgg.org.nz/library.cfm [Acceso julio 2004.]
3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Disponible en: http://www. ginasthma.com/[Acceso julio 2004.]
4. Grupo español para el manejo del Asma (GEMA). Guía Española para el Manejo del Asma. Arch Bronconeumol. 2003; 39 Supl 5:1-42.
5. National Asthma Council Australia (NAC). Asthma Management Handbook. Disponible en: http://www.nationala.sthma.org.au/publications/amh/amhcont.htm [Acceso 2002.]
6. Van den Toorn LM. Clinical implications of airway inflammation in mild intermittent asthma. Ann Allergy Asthma Immunol. 2004;92:589-94.
7. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev. 2000;(2): CD001107.
8. Enting D, Schokker S, Duiverman EJ, Van der Molen T. The effectiveness of inhaled corticosteroid therapy in preschool children with asthma: A systematic review of literature. Primary Care Respiratory Journal. 2003;12(2):52-7.
9. Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics. 2004;113:e87-e94.
10. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Respir Crit Care Med. 2000;162:1500-6.
11. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: A randomized, double-blind trial. Lancet. 2003;361:1071-6.
12. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343:1054-63.
13. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985-97.
14. O'Byrne PM, Barnes PJ, Rodríguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-7.
15. Pauwels RA, Busse WW, O'Byrne PM, Pedersen S, Tan WC, Chen YZ, et al. The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: Rationale and design. Control Clin Trials. 2001;22:405-19.
16. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev. 2004;(2):CD004109.
17. Adams N, Bestall JM, Jones PW. Inhaled fluticasone at different doses for chronic asthma. Cochrane Database Syst Rev. 2002; 1:CD003534.
18. Adams N, Bestall J, Jones PW. Budesonide at different doses for chronic asthma. Cochrane Database Syst Rev. 2001;(4): CD003271.
19. Adams N, Bestall J, Jones P. Inhaled beclomethasone at different doses for long-term asthma. Cochrane Database Syst Rev. 2001;(1):CD002879.
20. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: An evidence-based approach. Med J Aust. 2003;178:223-5.
21. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004;59:16-20.
22. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: A metaanalysis. Eur Respir J. 2004;23:552-8.
23. Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst Rev. 2004;(2): CD002310.
24. Reynolds NA, Scott LJ. Ciclesonide. Drugs. 2004;64:511-9.
25. Boulet LP, Cowie RL, Negro RD, Brett W, Gold M, Marques A, et al. Comparison of once- with twice-daily dosing of fluticasone propionate in mild and moderate asthma. Can Respir J. 2000;7:239-47.
26. ZuWallack R, Adelglass J, Clifford DP, Duke SP, Wire PD, Faris M, et al. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest. 2000;118:303-12.
27. Wolfe J, Rooklin A, Grady J, Munk ZM, Stevens A, Prillaman B, et al. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol. 2000;105:1153-61.
28. Mintz S, Alexander M, Li JH, Mayer PV. Once-daily administration of budesonide Turbuhaler was as effective as twice-daily treatment in patients with mild to moderate persistent asthma. J Asthma. 2002;39:203-10.
29. Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ. Inhaled fluticasone propionate by diskus in the treatment of asthma: A comparison of the efficacy of the same nominal dose given either once or twice a day. Chest. 2003;124:1584-93.
30. Singer R, Wood-Baker R. Review of the effect of the dosing interval for inhaled corticosteroids in asthma control. Intern Med J. 2002;32(3):72-8.
31. Dubus JC, Anhoj J. A review of once-daily delivery of anti-asthmatic drugs in children. Pediatr Allergy Immunol. 2003;14:4-9.
32. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-9.
33. o 01-E044 Rockville: Agency for Healthcare Researh and Quality; 2001.
34. Leone FT, Fish JE, Szefler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: Collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest. 2003;124:2329-40.
35. Price J, Hindmarsh P, Hughes S, Efthimiou J. Evaluating the effects of asthma therapy on childhood growth: What can be learn from the published literature? Eur Respir J. 2002;19:1179-93.
36. Roux C, Kolta S, Desfougeres JL, Minini P, Bidat E. Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. Pediatrics. 2003;111:e706-e13.
37. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics. 2004;114:469-73.
38. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(1):CD003537.
39. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med. 2004;169:83-8.
40. Adverse Drug Reactions Advisory Committee. Fluticasone and adrenal crisis. Aust Adverse Drug React Bull. 2003;22(2):6.
41. Van der Wouden JC, Tasche MJ, Bernsen RM, Uijen JH, De Jongste JC, Ducharme FM. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev. 2003;(3): CD002173.
42. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: Systematic review of current evidence. BMJ. 2003;326:621.
43. Maspero JF, Duenas-Meza E, Volovitz B, Pinacho DC, Kosa L, Vrijens F, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: Results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin. 2001;17:96-104.
44. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;(4):CD001186.
45. McCarney RW, Linde K, Lasserson TJ. Homeopathy for chronic asthma. Cochrane Database Syst Rev. 2004;(1):CD000353.
46. McCarney RW, Brinkhaus B, Lasserson TJ, Linde K. Acupuncture for chronic asthma. Cochrane Database Syst Rev. 2004;(1): CD000008.
47. Norheim AJ. Adverse effects of acupuncture: A study of the literature for the years 1981-1994. J Altern Complement Med. 1996;2:291-7.
48. Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev. 2002;(4):CD001002.
49. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):E48.
50. National Institutes of Health. National Asthma Education and Prevention Program Expert Report 2 (NAEP EPR-2). Guidelines for the Dagnosis and Management of Asthma. Update on selected topics; 2005.
51. Lemiere C, Bai T, Balter M, Bayliff C, Becker A, Boulet LP, et al. Adult Asthma Consensus Guidelines Update 2003. Can Respir J. 2004;11 Suppl A:9-18.
52. Walters EH, Walters JA, Gibson MD. Inhaled long acting beta agonists for stable chronic asthma. Cochrane Database Syst Rev. 2003;(4):CD001385.
53. U.S. Food and Drug Administration. Study of asthma drug halted. Disponible en: www.fda.gov/bbs/topics/answers(2002/ans01192.html [Acceso enero de 2003.]
54. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 2002;34:342-50.
55. Zimmerman B, D'Urzo A, Berube D. Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol. 2004;37:122-7.
56. Von Berg A, Papageorgiou SF, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol Turbuhaler in children. Int J Clin Pract. 2003;57:852-6.
57. Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD. et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol. 2002;89:180-90.
58. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Grit Care Med. 2005;171:129-36.
59. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368-73.
60. Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers. Can Respir J. 1999; 6:45-51.
61. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999;93:876-84.
62. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus inhaler(Seretide) is effective and safe in children with asthma. Pediatr Pulmonol. 2000;30:97-105.
63. Bateman ED, Britton J, Almeida J, Wison C. Salmeterol/Fluticasone Combination Inhaler: A new, effective and well tolerated treatment for asthma. Clinical Drug Investigation. 1998;16:193-201.
64. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29-36.
65. Shah L, Wilson AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev. 2003;(3):CD001281.
66. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: Systematic review of current evidence. BMJ. 2002;324:1545.
67. Vaquerizo MJ, Casan P, Castillo J, Perpina M, Sanchís J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58:204-10.
68. Price DB, Hernández D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211-6.
69. Ram FSF, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma [Systematic Review]. Cochrane Database of Systematic Reviews 2005;(1)(1).
70. Leuppi JD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH, et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly. 2003;133:302-9.
71. Fitzgerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five-month multicentre Canadian study. Can Respir J. 2003;10:427-34.
72. Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: The ASSURE study. Respir Med. 2004;98:464-75.
73. Stallberg B, Olsson P, Jorgensen LA, Lindarck N, Ekstrom T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract. 2003;57:656-61.
74. Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN, et al. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Curr Med Res Opin. 2004;20:1209-20.
75. Fitzgerald JM, Boulet LP, Follows RM. The CONCEPT trial: A 1-year, rnulticenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther. 2005;27:393-406.
76. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med. 2004;170:836-44.
77. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: Randomized controlled trial. BMJ. 2003;326:1115.
78. Casale TB, Nelson HS, Kemp J, Parasuraman B, Uryniak T, Liljas B. Budesonide Turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma. Ann Allergy Asthma Immunol. 2003;90:323-30.
79. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994;331:700-5.
80. Waalkens HJ, Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group. Am Rev Respir Dis. 1993;148:1252-7.
81. Van den Toorn LM, Overbeek SE, De Jongste JC, Leman K, Hoogsteden HC, Prins JB. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med. 2001;164:2107-13.
82. Brocklebank D, Ram F, Wright J, Berry P, Cates C, Davies L. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: A systematic review of the literature. Health Technol Assess. 2002;5(26).
83. Peters J, Stevenson M, Beverly C, Lim JNW, Smith S. The clinical effectiveness and costeffectiveness of inhaler devices used in the routine management of chronic asthma in older children: A systematic review and economic evaluation. Health Technol Assess. 2002;6(5).